Not exact matches
There are more than 80 immune - related cancer
therapies currently in clinical
trials, fueled by many billions of dollars in pharmaceutical investment from the
likes of Bristol - Myers Squibb bmy, Merck mrk, Pfizer pfe, and dozens of biotechs.
On the logistics end, it is easier to manufacture certain stem - cell
therapies, which will be key for human
trials like the heart - muscle - regeneration program.
While it takes time for gene
therapies to be tested,
trialed, and possibly approved by the FDA, genetics startups
like Spark, AveXis, Caribou Biosciences, Editas, and Audentes have been on the road a while.
«We're at a pivotal point where we're building upon what we've learned in the PLAT - 02
trial and opening new
trials,
like PLAT - 04, with the goal of improving this
therapy to the point that it becomes a long - term cure for all of our leukemia patients,» said Dr. Corinne Summers, an oncologist at Seattle Children's and the lead investigator of the PLAT - 04
trial.
«I think it would be marvelous if this
trial worked, but it really seems more
like a «Hail Mary pass» than a rational
therapy,» he says.
«It is a tough calculus, but gene
therapy for CF lung disease is still a realistic possibility and studies should be encouraged — especially well - done ones
like the U.K.
trial.
We provide access to the latest medicines and technology, as well as the most advanced clinical
trials including novel personalized targeted
therapies including precision medicine and immunotherapy - some that are only offered at NCI - designated Comprehensive Cancer Centers
like ours.
How would this development (and whatever drug or
therapy they devise for humans) move from the lab and into
trials, without it taking decades,
like the author here proposes?
Like most phase - I
trials, this
therapy will be tested first in patients with disease that has not responded to standard or other investigational
therapies.
The goal of the epacadostat / Keytruda
trial, and more than 1,100 combination
trials like it, was to see if combining an existing drug with a new
therapy would improve survival.
«We anticipate,» says Dr. Chou, «that this research will provide important pre-clinical data to support clinical
trials using DAC and similar drugs combined with immune
therapies targeting antigens
like NY - ESO - 1 to treat advanced colorectal cancer and potentially other common cancers.»